key: cord-0811802-4i8o2cqy
authors: Pereira, Naveen L.; Ahmad, Ferhaan; Cummins, Nathan W.; Byku, Mirnela; Morris, Alanna A.; Owens, Anjali; Tuteja, Sony; Cresci, Sharon
title: COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine
date: 2020-12-03
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.11.024
sha: c096f75d74ee7e71276adf31ff19ba8eeb7f2dbe
doc_id: 811802
cord_uid: 4i8o2cqy

COVID-19 is characterized by heterogeneity in susceptibility to the disease and severity of illness. Understanding inter-individual variation has important implications for not only allocation of resources but also targeting patients for escalation of care, inclusion in clinical trials, individualized medical therapy including vaccination. In addition to geographic location and social vulnerability, there are clear biological differences such as age, sex, race, presence of comorbidities, underlying genetic variation and differential immune response that contribute to variability in disease manifestation. These differences may have implications for precision medicine. Specific examples include the observation that androgens regulate the expression of TMPRSS2 which facilitates SARS-CoV-2 viral entry into the cell; therefore androgen deprivation therapy is being explored as a treatment option in males infected with COVID-19. An immunophenotyping study of COVID-19 patients has demonstrated that a subset develop T cytopenia which has prompted a clinical trial that is testing the efficacy of interleukin-7 in these patients. Predicting which COVID-19 patients develop progressive disease that required hospitalization has important implications for clinical trials that target outpatients. Enrollment of patients at low risk for progression of disease and hospitalization would likely not result in such therapy demonstrating efficacy. There are efforts to use artificial intelligence to integrate digital data from smart watch applications or digital monitoring systems and biological data to enable identification of the high risk COVID-19 patient. The ultimate goal of precision medicine using such modern technology is to recognize individual differences to improve health for all.

Males are at a greater risk of COVID-19 related morbidity and mortality as compared to females across various age groups (Figure 4) . 3 5-8 Studies describing sex differences have been descriptive and did not adjust for confounding concomitant morbidities. Men are more likely to be smokers and have a higher risk of hypertension, cardiovascular disease and diabetes mellitus all of which are risk factors for adverse outcomes in COVID-19 disease. 9 10 However the prevalence of these comorbidities is low in the younger age groups in which sex-related differences in outcomes were observed. The susceptibility to adverse outcomes may be related to an increased inflammatory response (Figure 5 ) in males and a lack of the protective effect of estrogen receptor signaling present in females. 11 12 SARS-CoV-2 virus binds to the angiotensinconverting enzyme (ACE) 2 receptor and a recent study in heart failure patients who did not have COVID-19 disease demonstrated that circulating ACE2 levels are higher in men as compared to women independent of other factors. 13 The difference in ACE2 levels may be related to sex related differential expression of the ACE2 gene since it is located on the X chromosome or sex related differential regulation of interferon production that affects ACE2 gene expression. 14 There is also increased bi-allelic X chromosome linked TLR7 gene expression observed in females as these genes escape inactivation as opposed to males possessing only a single copy of these genes. 15 Toll-like receptor 7 is abundantly present in lung tissue and upon recognition of viral RNA produces type 1 interferon thus launching an early antiviral response. [16] [17] [18] Females have higher B cell counts and also tend to have a greater antibody response than males to vaccination that may be related to the effect of testosterone on antibody production. 19 20 Even more concerning, is that asymptomatic patients may have: 1) a longer median duration of viral shedding than symptomatic ones; 2) weaker immune responses, with significantly lower virus-specific IgG antibody titers and cytokine levels. 35 Data on patients <18 years old is sparse, but overall seems to suggest that COVID-19 disease is asymptomatic or mildly symptomatic in the pediatric population. The reported rate of hospitalization in this population is low (5.7 %-20%), with infants <1 years old and children with chronic underlying conditions being at higher risk for more severe illness. Severe pediatric infections (requiring hospitalization) are more prevalent in males (57%) than females, consistent with findings in adults. 36 features.{Feldstein, 2020 #163;Dufort, 2020 #164} The relationship between the genetic architecture of KD and this manifestation of COVID-19 remains to be defined, however there is growing concern that the ensuing SARS-CoV-2 infection related inflammatory response and cytokine storm may result in this more severe form of disease{Xu, 2020 #165} especially among blacks, Hispanics, or South Asians{Feldstein, 2020 #163;Dufort, 2020 #164;Whittaker, 2020 #166;, #167} and those with increased BMI.{Belhadjer, 2020 #168} the greater virulence of SARS-CoV-2 compared to SARS-CoV may be explained by the significantly higher affinity that the COVID-19 viral S1 protein exhibits for ACE2. There is a clear spectrum of ACE2 expression in both humans and other mammals. 39 Therefore, the human ACE2 expression level and pattern in various tissues may be important when considering variation in susceptibility and disease severity across infected patients. For example, children under the age of 10 most of whom are asymptomatic or have mild disease have the lowest expression of ACE2 receptors in their nasal epithelial.{Patel, 2020 #169} However, some develop a severe Kawasaki-like syndrome characterized by profound inflammation of multiple organs, including the cardiovascular system, termed multisystem inflammatory syndrome in children (MIS-C). Clinical features that predict which children develop MIS-C are not well understood but some have proposed that sex (males > females), obesity and genetic factors are important.

The global COVID-19 pandemic has revealed substantial variability in incidence and mortality according to factors such as geographical location and social vulnerability. This variability has largely been shaped by variable policy related to travel restrictions, voluntary vs mandatory social distancing, and availability of testing and contact tracing, as well as differences in healthcare systems and management. 40 41 In addition to public policy efforts, there may be biologic determinants that contribute to variability in COVID-19 severity across countries as described in this manuscript. (eQTL) variants leading to higher ACE2 tissue expression compared to European populations, which would suggest that Asian populations may be more susceptible to more severe disease due to increase viral uptake via the ACE2 route. 39 Some data suggests countries with universal policies utilizing BCG (Mycobacterium bovis Bacillus Calmette Guérin) vaccination have fewer COVID-19 cases and a lower case fatality rate than countries that lack universal BCG vaccination. 42 The BCG vaccine is thought to induce "trained immunity", a concept that refers to a long-term epigenetic and metabolic reprogramming of innate immune cells that result in heightened proinflammatory activity. 43 44 BCG vaccinations protective effect hypothesis was questioned in an Israeli population based cohort that showed no difference in the rate of COVID-19 test positivity between those in BCG-vaccinated vs unvaccinated cohort.

In addition to variability in incidence, mortality from COVID-19 varies widely by county across the US ( Table 1) . For example, during the height of the outbreak in March and April 2020, the number of patients who were hospitalized and had COVID 19 related deaths were highest in the Bronx and lowest in Manhattan. 45 Even more striking is the clear disparity in case incidence and case fatality by race-ethnicity as described above. [46] [47] [48] The disproportionate rates of COVID-19 infections in people of color can be attributed to the insidious and widespread effects of systemic health and social inequities throughout the US. For example, people of color are more likely to have cardiovascular comorbidities that increase susceptibility to severe disease. In addition, they are more likely to be front-line workers and live in neighborhoods with a higher degree of social vulnerability. Despite these hypotheses, there is controversy as to whether racial differences in outcomes persist after adjusting for differences in medical and socioeconomic comorbidities. [49] [50] [51] In adjusted analyses, the odds of hospitalization was higher for J o u r n a l P r e -p r o o f Blacks as compared to Whites. However after accounting for differences in medical comorbidities and neighborhood characteristics, the risk of in-hospital mortality was similar between Blacks and Whites. Given the striking disparities noted early in the pandemic, ongoing efforts aim to characterize COVID-19 disease with social determinants of health, including poverty, residential segregation, and availability of medical services and examine its effects on outcomes. 52 

The transmembrane protease serine 2 (TMPRSS2) and the endosomal cysteine proteases cases and 950 controls from Spain, there was an association with rs11385942 at chromosome 3p21.31. 63 Among the six genes associated with this locus, SLC6A20 encodes the sodium/aminoacid (proline) transporter 1 (SIT1) that functionally interacts with ACE2.

In silico analyses have identified 21 single nucleotide polymorphisms (SNPs) that may impact splicing, microRNA regulation, posttranslational modifications, and protein folding of TMPRSS2. 64 Other investigators have identified coding SNPs that are predicted to cause a loss of function of TMPRSS2 and eQTL variants that impact TMPRSS2 expression. 65 In both studies, differences in allele frequencies in different populations were hypothesized to underlie differences in the prevalence of COVID-19. However, no direct clinical correlations have been made in COVID-19 patients.

In other infections, the ABO protein may serve as a receptor or a co-receptor for bacteria, parasites, and viruses. Recent studies have suggested that ABO antigens modify the cellular distribution of receptors and, depending on which blood group antigens are expressed, differentially modulate spike protein binding to the host cell. 66 

The toll like receptor (TLR) pathway activates the immune system and inflammation.

Genetically engineered mice that are null for various members of the TLR pathway exhibit greater susceptibility to infection by SARS-CoV. 72 73 Therefore, it is speculated that variants in TLR genes in humans may also modulate susceptibility to infection by SARS-CoV-2. 74 is approximately 31%-53%. 78 Interestingly, TMPRSS2 has an androgen response element, and androgens are known to increase TMPRSS2 transcription.

A haplotype on chromosome 3 inherited from Vindija 33.19 Neanderthals, who lived approximately 50,000 years ago in southern Europe, confers an odds ratio for requiring hospitalization from COVID-19 of 1.6 (95% confidence interval 1.42-1.79).{Zeberg, 2020 #170}

The Neanderthal haplotype appears in South Asia at a frequency of 30%, in Europe at 8%, among admixed Americans at 4%, in East Asia at very low frequencies, and in Africa at almost zero frequency. Thus, differences in the frequency of the Neanderthal haplotype may underlie differences in susceptibility to severe COVID-19 among populations.

Heterogeneity in infection risk or disease severity may not just to be due to differences in the host but may also partially derive from virologic diversity. Mutations in viral genomes have long been recognized to contribute to transmission and escape from pre-existing immune responses 

The high prevalence of COVID-19 positive patients who are not hospitalized makes it an important group to study but the low event rate in these patients and the uncertainty in predicting those who will develop complications poses significant challenges to demonstrate efficacy of a therapeutic intervention. An example of this challenge is the recently completed placebo versus hydroxychloroquine clinical trial in which 821 asymptomatic subjects most of whom had a high risk exposure to a COVID-19 patient were enrolled. 79 Hydroxychloroquine, blocks viral entry by inhibiting glycosylation of host receptors and endosomal acidification and demonstrates in vitro activity against SARS-CoV-2. 80 The incidence of new COVID-19 disease in this trial was low at 13% and just 2 hospitalizations occurred in the overall study population during follow-up. Study participants were predictably low risk the median age being 40 years, majority of the participants were women and more than 70% did not have comorbidities. This study which was powered to show a 50% relative reduction in new symptomatic infections had low risk participants enrolled and a low event rate resulting in no benefit being demonstrated for the use of hydroxychloroquine as compared to placebo. Therefore development of a predictive tool using demographic, clinical, biochemical and genetic parameters to identify high risk patients may be especially important to deliver individualized care rather than therapy for all. A randomized controlled trial (NCT04332991) being funded by the National Heart Lung Blood Institute (NHLBI) to evaluate the safety and effectiveness of hydroxychloroquine was stopped on June 20, 2020 after enrolling 479 of its intended 500 participants, stating that the drug was unlikely to be of benefit to hospitalized patients with COVID-19. 81 Also in June 2020, the FDA revoked the J o u r n a l P r e -p r o o f emergency use authorization for hydroxychloroquine, citing emerging scientific data that the drug is unlikely to be effective in treating COVID-19. 81

A study in which hospitalized COVID-19 patients among whom more than 88 % were critically ill had a shorter time to recovery when treated with remdesivir as compared to placebo. 82

Remdesivir is an investigational inhibitor of viral RNA-dependent RNA polymerase and was shown to be active against SARS and MERS. 83 There were statistically significant differences in the prespecified sub-groups indicating heterogeneity in response. For example, White patients seem to derive benefit with remdesivir as opposed to Blacks or Asians and a similar trend was observed in non-Hispanic patients as compared to Hispanics. Although such findings do not lead to the conclusion that the drug should or should not be used in these sub-groups, they do emphasize the importance of representing various racial and ethnic groups in COVID-19 clinical trials to assess for biological differences in disease presentation and response to interventions.

The role of corticosteroids in the treatment of acute lung injury and ARDS is controversial. 84 85 The Randomized Evaluation of COVID-19 therapy (RECOVERY) trial demonstrated that dexamethasone 6mg daily for a median of 7 days (interquartile range, 3 to 10 days) reduced the 28-day mortality rate by 17% as compared to usual care. 86 There appeared to be of variable response with a greater reduction in mortality in the subgroup of patients on oxygen (rate ratio 0.82, 95% CI, 0.72-0.94) and invasive mechanical ventilation (rate ratio 0.64, 95% CI, 0.51-0.81) at the time of randomization but no benefit in those not receiving respiratory support (rate ratio 1.19, 95% CI 0.91-1.55). The patients who were on respiratory support at J o u r n a l P r e -p r o o f randomization were younger, a greater proportion was male and they had less co-morbidity such as heart disease as compared to those not receiving respiratory support which may account for the favorable response to treatment. The S2 domain is highly conserved amongst coronaviruses 93 while the S1 domain is the most unique. 94 The S1 RBD of SARS-CoV-2 is also responsible for inducing the host immune response. 95 96 In fact, the SARS-CoV-2 RBD is the primary inducer of neutralizing antibodies, antibodies that can bind to the virus and prevent infection by blocking the viral replication process. [94] [95] [96] Currently available antibody tests predominantly target the spike protein and/or the nucleocapsid protein. 97 Antibody tests that target the nucleocapsid protein are more sensitive, while those targeting the S1 protein have been touted as more specific. 94 97 

The benefit of SARS-CoV-2 antibody testing at the individual level is currently being debated.

Although some have proposed that individuals who have SARS-CoV-2 antibodies will be immune to recurrent disease there is currently no data to support this assumption. There is also no consensus on what level of antibodies (and which antibodies) would confer individual immunity. Furthermore, there have been concerns about false positive results (and resulting false J o u r n a l P r e -p r o o f reassurance) that may occur due to cross-reactivity with the presence of antibodies to other coronaviruses, such as the alpha and beta coronaviruses that cause the common cold, severe acute respiratory syndrome coronavirus (SARS-CoV), and middle east respiratory syndrome coronavirus (MERS-CoV); recently machine learning approaches have been utilized to address this concern.{Shrock, 2020 #179;Weissleder, 2020 #84} Unknown sensitivity, specificity, positive and negative predictive values have contributed to reluctance to recommend utilization of these tests for individual patient-care decisions. [98] [99] [100] One instance where SARS-CoV-2 antibody tests may have utility in individual cases is in helping with the diagnosis of COVID-19 infection if the patient presents late in the course of their disease when PCR testing for viral antigens may be negative. 101 102 

Data on whether seroconversion is different based on different patient characteristics is just beginning to emerge. Several investigators have observed that individuals with more severe disease and worse outcomes have higher titers of SARS-CoV-2 antibodies compared to those with less severe disease. 35 103-106 Individuals with mild disease also appear to be much more likely than those with more severe disease to revert to seronegativity in the convalescent period or to never seroconvert at all. 105 This difference in response is even more apparent in asymptomatic individuals with reports of -80% of asymptomatic individuals never generating an antibody response at all 105 Some investigators have focused specifically on patient characteristics that determine production of neutralizing antibodies in response to SARS-CoV-2. In one study, patients who were 31 years and older developed higher neutralizing antibody level than those who were 16 to 30 years old. 106 This was confirmed in another study using slightly different age cut-offs (40 to 85 years old vs.15 to 39 years old). 28 Others have observed that asymptomatic individuals had lower neutralizing antibody levels compared to symptomatic individuals. 35 Importantly, it has been reported that up to 30% of individuals infected with SARS-CoV-2 developed very low or undetectable levels of neutralizing antibodies. 28 A recent study used a deep immune profiling approach and integrated it with clinical data to define distinct immunotypes (characterized by variable activation of, and proliferation of, different subsets of B and T cells) that predicted response to COVID-19. 107 

The race to develop a safe and efficacious vaccine against SARS-CoV-2 has been unprecedented, with more than 150 potential vaccines in various stages of clinical and preclinical development worldwide in less than 6 months since the start of the pandemic. 109 There are several challenges in vaccine development for COVID-19 that has specifically related to heterogeneity in response. 110 An important concern is the risk of disease enhancement J o u r n a l P r e -p r o o f vaccine formulations that lead to less variability in response. However, in the current state, it is difficult to make these comparative analyses between vaccine trials due to non-standardized assays measuring immunogenicity correlates. In addition to variability in response to vaccination, it will be important to consider targeting patients at high risk for COVID-19 outcomes given the initial logistic challenges of vaccinating the entire population.

Predicting the heterogeneity in presentation and outcomes becomes especially important in a pandemic when the availability of resources such as intensive care unit beds and ventilators may be limited. Once a COVID-19 test is positive, determining the at-risk patient (Figure 6 ) becomes important not only from a surveillance perspective to be able deliver effective care expeditiously but also enables individualized targeting of those patients for medical intervention that may attenuate disease course. The rapidity of disease progression almost makes it imperative to be able to use electronic health records (EHR) to develop predictive algorithms in order to identify high risk patients. In one example, a clinical decision support tool was developed to assess COVID-19 disease severity using a multiplex and multiclass platform with demographic data such as age and sex and biological data such as cardiac troponin, C-reactive protein, procalcitonin and myoglobin levels of 160 hospitalized COVID-19 patients. 114 An increasingly important component of precision medicine is the ability to obtain individualized data using digital technology such as smart watch applications or digital J o u r n a l P r e -p r o o f monitoring systems that collect heart rate, temperature, pulse oximetry and sleep patterns that may efficiently and quickly identify overly detection of infection and clinical decline using artificial intelligence algorithms (WSJ Pro Artificial Intelligence Hospitals) monitor some coronavirus patients at home; 115 Thomas Reuters Germany launched a new smartwatch application to monitor coronavirus spread. 116 117 Predictive and preemptive platforms using artificial intelligence to analyze EHRs on a large scale coordinated with information obtained from individual patients using digital and sensor technology need to be undertaken. Identifying the high risk patient is important in the context of the high risk patient being exposed to and subsequently developing COVID-19 disease. The risk of infection can be preemptively identified for geographical locations in which high risk patients reside by using mobile phone data to track population outflows from hot spots. 118 A high risk patient could also be identified by mobile phone application technology that stores contacts of COVID-19 patients using Bluetooth signals when they may be in the asymptomatic infectious phase of the illness. 119 The clinical use of digital technology that collects individual patient information remains challenging due to patient confidentiality issues and therefore appropriate electronic informed consent should be obtained and data should be collected using a Health Insurance Portability and Accountability Act As discussed above, an important host factor that determines susceptibility and severity of COVID-19 19 illness is the host genome. Although our understanding of the genetic determinants of COVID-19 has improved, its role in susceptibility to the disease remains limited.

Identifying such genetic loci in an agnostic manner may not only assist in determining the risk profile of the patient but also could provide insight into the pathophysiology of disease and identify potential therapeutic targets. The findings of the genetic studies summarized above will require validation in additional cohorts with long-term follow-up. To successfully perform such studies large consortia are required and one such collaboration is the COVID-19 host genetics initiative that comprises of array-based genotyping in 69% and exome/whole genome sequencing in 29% of the participants studies. The ultimate goal of such digital and genomic tools in the modern era is to be able to recognize individual differences to improve health for all using precision medicine.

COVID-19 disease is making a rapid resurgence around the world. There are demographic characteristics such as age, race, ethnicity and sex and biological differences such as ACE-2 expression, immune regulation and genetics that define the well-known variability in COVID-19 disease manifestation, susceptibility and progression. Identifying and validating these individual differences and leveraging digital platforms including the use of artificial intelligence in developing predictive algorithms may help in individualizing targeted therapy and hospitalization and assist in the logistics of vaccine administration. 

Coronavirus pandemic (COVID-19) -the data. Our World in Data website

TLR7 escapes X chromosome inactivation in immune cells

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

Origin and functional specializations of DC subsets in the lung

TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN

Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination

Gender effect on in vitro lymphocyte subset 31

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

A novel COVID-19 and its effects on cardiovascular disease

PhD1,2; Sukarma Tanwar, MMed1,2; Zeshan Chisty, MPH1; Jeneita M. Bell, MD1; Mark Methner, PhD1

MD1; Public Health -Seattle & King County; CDC COVID-19 Investigation Team. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility

ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

ACE 2 coding variants: A potential x-linked risk factor 1 for COVID-19 disease

Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility

DNA methylation analysis of the COVID-19 host cell receptor, angiotensin I converting enzyme 2 gene (ACE2) in the respiratory system reveal age and gender differences

The landscape of host genetic factors involved in infection to common viruses and SARS-CoV-2

ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy

The influence of ABO blood groups on COVID-19 susceptibility and severity: A molecular hypothesis based on carbohydratecarbohydrate interactions

Relationship between the ABO blood group and the COVID-19 susceptibility

Testing the association between blood type and COVID-19 infection, intubation, and death

Clinical and genetic characteristics of Covid-19 patients from UK Biobank

COVID-19 diagnostics in context

Seroepidemiologic study designs for determining SARS-COV-2 transmission and immunity

Structure, function, and evolution of coronavirus spike proteins

Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment

Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients

Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset

Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019

Antibody tests for COVID-19: drawing attention to the importance of analytical specificity

Antibody Testing for COVID-19

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays

Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients

Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions

COVID-19 vaccines

Immunosenescence and human vaccine immune responses

An mRNA vaccine against SARS-CoV-2 -Preliminary report

Clinical decision support tool and rapid point-of-care platform for determining disease severity in patients with COVID-19

Population flow drives spatio-temporal distribution of COVID-19 in China

Data presented are the top 10 US counties with the most confirmed total number of cases, followed by the current number of new cases per 100,000 in the county population. Similarly, the top 10 US counties with the most confirmed total number of deaths, followed by the case-fatality rate for those counties is presented.J o u r n a l P r e -p r o o f